ArticleThe American journal of cardiology2008
Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes.
Article in The American journal of cardiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04542213 (Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of incretin therapy during peri-operative and intensive care.Critical care (London, England) · 2018Pooled it
- Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial.Diabetes, obesity & metabolism · 2020 · on this mapTrial
- Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.Cardiovascular diabetology · 2018Trial
- The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study.Critical care medicine · 2014Trial
- Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.Critical care (London, England) · 2011Trial
- The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.Critical care (London, England) · 2009Trial
- The use of GLP-1 receptor agonists in hospitalised patients: An untapped potential.Diabetes/metabolism research and reviews · 2019Review
- Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.Current diabetes reports · 2017Review
- Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards.Journal of the Endocrine Society · 2017Review
- Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.Frontiers in physiology · 2017Review
- The potential role of incretin therapy in the hospital setting.Clinical diabetes and endocrinology · 2015Article
- Effects of incretin-based therapy in patients with heart failure and myocardial infarction.Endocrine · 2014Review
- Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients.Diabetes spectrum : a publication of the American Diabetes Association · 2014Article
- The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretins.Current diabetes reports · 2014Review
- Incretins and the intensivist: what are they and what does an intensivist need to know about them?Critical care (London, England) · 2014Review
- Regulation of glucose homeostasis by GLP-1.Progress in molecular biology and translational science · 2014Review
- Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment.Diabetes care · 2013Article
- Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Diabetes care · 2013Article
- Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).Cardiovascular diabetology · 2013Article
- The cardiovascular effects of GLP-1 receptor agonists.Cardiovascular therapeutics · 2012Review
Corrections and comments
- Comment on
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
18721530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.